Where Gilead Sciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
Gilead Sciences (NASDAQ:GILD) has received mixed reviews from analysts in the last quarter, with 8 indifferent ratings, 1 somewhat bullish, and 1 somewhat bearish. The average price target is $83.8, which is higher than the current price of $75.16. However, this average has decreased by 3.95% from the previous average price target of $87.25.
September 06, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a decreased price target could lead to uncertainty for Gilead Sciences.
The mixed analyst ratings indicate that there is no clear consensus on the performance of Gilead Sciences. The decrease in the average price target could also lead to uncertainty among investors, potentially impacting the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100